Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 213

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 213
---
78 | %  |
| Net loss                                                               |     |                     |  (8,304,423 | ) |     |               | (7,289,577 | ) |     |            | (1,014,846 | ) |     |            |     13.9 | %  |
| Deemed dividend                                                        |     |                     |  (2,784,839 | ) |     |               |          - |   |     |            | (2,784,839 | ) |     |            |        - |    |
| Net loss attributable to common stockholders                           |     | $                   | (11,089,262 | ) |     | $             | (7,289,577 | ) |     | $          | (3,799,686 | ) |     |            |     52.1 | %  |

General and Administrative Expenses General and administrative expenses were $9.1 million for the year ended December 31, 2024, compared to $2.4 million for the year ended December 31, 2023, reflecting an increase of $6.7 million. The increase in the year ended December 31, 2024, over the year ended December 31, 2023, was partially due to a $1.8 million expense consisting of the remaining underwriting fees from the PBAX initial public offering, which were earned on the consummation of the business combination. Additionally, the hiring of senior management in G&A resulted in an increase of $2.0 million, including recruiting fees. Legal fees increased $1.0 million and business consulting increased $0.8 million in the year ended December 31, 2024, versus the year ended December 31, 2023. Expenses related to services required for SEC compliance, such as printing and transfer agency fees, increased $0.5 million and public company insurance coverage increased insurance expenses $0.5 million in the year ended December 31, 2024, compared to the year ended December 31, 2023. Corporate communications and director fees each increased $0.2 million in the year ended December 31, 2024 compared to the year ended December 31, 2023. The additional expenses are all driven by the increased expenses of operational compliance as a public company. Research and Development Expenses Research and development expenses were $7.6 million for the year ended December 31, 2024, compared to $5.3